Aruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit
-AB126 is an unmodified exosome derived from neural stem cell lines with the innate ability…
-AB126 is an unmodified exosome derived from neural stem cell lines with the innate ability…
PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology…
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients…
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid…
Review of Interim Efficacy Data by IDMC to Occur in Fourth Quarter SAN DIEGO, Oct….
Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented…
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) — Axial Therapeutics Inc., a clinical-stage biopharmaceutical company…
The collaboration and licensing agreement is Surrozen’s first strategic partnership for one of its compounds…
100,000 square foot facility to support company plans for growth in clinical laboratory services, drug…
With threat landscape evolving at a rapid pace, modernizing security needs to be a key component…
MINNEAPOLIS, Oct. 06, 2022 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Augmentt Secure Premium also includes new features and functionality that make it easier for MSPs…
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced…
Rural FL launch serves as proof of concept for underserved regions nationally NEW YORK, NY…
CARLSBAD, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified…
Quarterly revenue expected to exceed US$27.0 million for quarter ended September 30, 2022, an all-time record TORONTO…
BOSTON and GENEVA, Switzerland, Oct. 06, 2022 (GLOBE NEWSWIRE) — SOPHiA GENETICS (Nasdaq: SOPH), a…
Epetraborole Data from Recently Completed Phase 1 Study in Japanese Subjects Supports Use of Once…
DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,…
DEVON, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader…